Research programme: activating antigen carriers - SQZ BIOTECH
Alternative Names: Next-Gen-SQZ-AACs; SQZ AACsLatest Information Update: 28 Dec 2023
At a glance
- Originator SQZ Biotech
- Class Antineoplastics; Cell therapies; Gene therapies; Immunotherapies
- Mechanism of Action Cell replacements; T lymphocyte stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Cancer
Most Recent Events
- 28 Dec 2023 No recent reports of development identified for preclinical development in Cancer in USA (Parenteral)
- 19 May 2020 SQZ Biotech announces intention to submit an IND application to regulatory body for Cancer
- 15 Nov 2019 Pharmacodynamics data from preclinical trials in Cancer released by SQZ biotech